Table 3. COX regresion based on overall survival.
| Parameters | Total patients | 5-year OS | Log-rank P value | univariate analysis | multivariate analysis | ||
|---|---|---|---|---|---|---|---|
| N = 206 | NUM of death | HR(95%CI) | P-value | HR(95%CI) | P-value | ||
| Age(years) | 0.047 | ||||||
| < 63 | 96 | 49 | Reference | Reference | |||
| > 63 | 110 | 38 | 1.528(1.000,2.334) | 0.05 | 1.237(0.766,1.999) | 0.385 | |
| Gender | 0.921 | ||||||
| Male | 131 | 56 | Reference | ||||
| Female | 75 | 31 | 0.978(0.631,1.517) | 0.922 | |||
| Smoking | 0.03 | ||||||
| No | 157 | 59 | Reference | Reference | |||
| Yes | 49 | 28 | 1.631(1.040,2.558) | 0.033 | 1.841(1.149,2.949) | 0.011 | |
| Drinking | 0.555 | ||||||
| No | 182 | 75 | Reference | ||||
| Yes | 24 | 12 | 1.199(0.652,2.206) | 0.559 | |||
| BMI(kg/m2) | 0.008 | ||||||
| < 22.16 | 103 | 34 | Reference | Reference | |||
| > 22.16 | 103 | 53 | 1.778(1.155,2.736) | 0.009 | 2.004(1.244,3.228) | 0.004 | |
| Hypertension | 0.011 | ||||||
| No | 160 | 60 | Reference | Reference | |||
| Yes | 46 | 27 | 1.787(1.134,2.816) | 0.012 | 1.544(0.959,2.486) | 0.074 | |
| Diabetes | 0.005 | ||||||
| No | 176 | 68 | Reference | Reference | |||
| Yes | 30 | 19 | 2.035(1.222,3.388) | 0.006 | 1.403(0.763,2.581) | 0.276 | |
| TMN stage | 0.038 | ||||||
| I-II | 81 | 26 | Reference | Reference | |||
| III | 125 | 61 | 1.613(1.018,2.556) | 0.042 | 1.147(0.900,1.463) | 0.267 | |
| Cell differentiation | 0.03 | ||||||
| H | 20 | 3 | Reference | Reference | |||
| M | 155 | 67 | 3.584(1.127,11.397) | 0.031 | 2.281(0.699,7.442) | 0.172 | |
| L | 31 | 17 | 4.662(1.365,15.914) | 0.014 | 3.912(1.130,13.551) | 0.031 | |
| Location | 0.569 | ||||||
| Rectal | 94 | 41 | Reference | ||||
| Colon | 112 | 46 | 0.886(0.581,1.350) | 0.572 | |||
| Chem | 0.365 | ||||||
| No | 55 | 20 | Reference | ||||
| Yes | 151 | 67 | 1.257(0.763,2.073) | 0.37 | |||
| Albumin (g/l) | 0.001 | ||||||
| < 35 | 69 | 40 | Reference | Reference | |||
| > 35 | 137 | 47 | 0.490(0.321,0.747) | 0.001 | 0.590(0.383,0.909) | 0.017 | |
| VDBP | 0.203 | ||||||
| Low | 40 | 13 | Reference | ||||
| Middle | 145 | 62 | 1.463(0.805,2.661) | 0.212 | |||
| High | 21 | 12 | 2.013(0.918,4.416) | 0.081 | |||
| Total 25(OH)D | 0.23 | ||||||
| Low | 59 | 22 | Reference | ||||
| Middle | 123 | 52 | 1.180(0.717,1.943) | 0.516 | |||
| High | 24 | 13 | 1.794(0.903,3.563) | 0.095 | |||
| Free 25(OH)D | 0.008 | ||||||
| Low | 19 | 13 | Reference | Reference | |||
| Middle | 72 | 23 | 0.353(0.178,0.699) | 0.003 | 0.241(0.117,0.495) | 0 | |
| High | 115 | 51 | 0.535(0.290,0.985) | 0.045 | 0.442(0.238,0.819) | 0.01 | |
| Bioavailable 25(OH)D | 0.019 | ||||||
| Low | 21 | 14 | Reference | Reference | |||
| Middle | 61 | 22 | 0.410(0.210,0.803) | 0.009 | 0.807(0.327,1.992) | 0.642 | |
| High | 124 | 51 | 0.485(0.268,0.877) | 0.017 | 0.398(0.082,1.928) | 0.253 | |
Abbreviations: OS: overall survival; HR: hazard ratio; 95%CI: 95% confidential interval; Chem: Chemotherapy; 25(OH)D: 25-hydroxyvitamin D; VDBP: vitamin D binding protein; ALB: albumin;BMI: body mass index; L: Low group; M: Middle group; H: High group.
Note: The bold represent that P value was statistically significant.